Synexo Group (SYNEXO) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Net sales increased to KSEK 3,749 in Q1 2025 from KSEK 2,846 year-over-year, but the group posted a net loss of KSEK -3,560, slightly higher than last year.
The company changed its name from LC-Tec Holding AB to AB Sperrung and completed a new share issue in its main subsidiary.
Key product developments include a collaboration with KipperTie for electronic ND filters and a significant order from a US MedTech company.
The group is focusing on cost control, external manufacturing, and seeking strategic partners or new owners.
No legal disputes or regulatory proceedings are ongoing.
Financial highlights
Net sales: KSEK 3,749 (Q1 2025) vs. KSEK 2,846 (Q1 2024); net result: KSEK -3,560 vs. KSEK -3,281.
Cash flow from operations: KSEK -836 (Q1 2025) vs. KSEK -1,577 (Q1 2024).
Equity at period end: KSEK 613 (Q1 2025) vs. KSEK 260 (Q1 2024); soliditet 5% (Q1 2025) vs. 2% (Q1 2024).
No investments in tangible or intangible assets during the quarter.
Cash and bank balances: KSEK 544 at March 31, 2025.
Outlook and guidance
Board sees strong future prospects due to product progress and ongoing investments in sales, production, and development.
No formal forecast is provided for the coming period.
Focus remains on cost control, external manufacturing, and seeking strategic partners.
Latest events from Synexo Group
- ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 202528 Nov 2025 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 202521 Aug 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 202413 Jun 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025